Clinical trial
Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal…
NCT00038792 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00038792 |
|---|---|
| Title | Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD |
| Official title | A Phase I/II Trial of Recombinant Human Keratinocyte Growth Factor (rHuKFG) for the Treatment of Steroid Refractory Gastrointestinal Acute Graft-versus-host Disease (aGvHD) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Amgen Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Graft Versus Host Disease |
| Intervention type | Drug |
| Interventions | Recombinant Human Keratinocyte Growth Factor |
| Enrollment | 7 |
| Start date | Oct 1, 2000 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2003 |
| First posted | Jun 7, 2002 |
| Last update posted | Aug 2, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: